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Abstract: Research on bladder neoplasms in pediatric and teen patients (BNPTP) has 
described 21 genes, which are variously involved in this disease and are mostly re-
sponsible for deregulated cell proliferation. However, due to the limited number of 
publications on this subject, it is still unclear what type of relationships there are 
among these genes and which are the chances that, while having different molecular 
functions, they i) act as downstream effector genes of well-known pro- or anti- proliferative stimuli and/or interplay with 
biochemical pathways having oncological relevance or ii) are specific and, possibly, early biomarkers of these patholo-
gies. A Gene Ontology (GO)-based analysis showed that these 21 genes are involved in biological processes, which can 
be split into two main classes: cell regulation-based and differentiation/development-based. In order to understand the in-
volvement/overlapping with main cancer-related pathways, we performed a meta-analysis dependent on the 189 onco-
genic signatures of the Molecular Signatures Database (OSMSD) curated by the Broad Institute. We generated a binary 
matrix with 53 gene signatures having at least one hit; this analysis i) suggests that some genes of the original list show 
inconsistencies and might need to be experimentally re- assessed or evaluated as biomarkers (in particular, ACTA2) and 
ii) allows hypothesizing that important (proto)oncogenes (E2F3, ERBB2/HER2, CCND1, WNT1, and YAP1) and (puta-
tive) tumor suppressors (BRCA1, RBBP8/CTIP, and RB1-RBL2/p130) may participate in the onset of this disease or 
worsen the observed phenotype, thus expanding the list of possible molecular targets for the treatment of BNPTP. 
Keywords: Bioinformatics, biomedical modeling, gene set, neoplastic transformation, PubMed query. 
1. INTRODUCTION 
 According to the US National Cancer Institute (NCI) 
website [1] bladder cancer (BC) is classified, in adults, 
among the most common cancers in the USA, where almost 
75,000 new BC cases and more than 15,000 BC-related 
deaths have been estimated for the year 2014. In particular, 
these statistics show that in 2013 about 55,000 men and 
18,000 women were diagnosed with bladder cancer, with a 
ratio of approximately 3:1; consequently, BC is reported by 
NCI as the sixth cause of new cancer cases, and the eighth 
cause of death among common malignancies [1]. However, 
this website classifies BC among ‘unusual cancers of child-
hood’; indeed, collecting statistical data about pediat-
ric/teenage BC using on-line resources is challenging, due 
the limited number of reported cases. As a matter of fact, the 
reported incidence of BC in the population, in the age range 
15-19 years, is 110-6, and even lower in younger patients 
[2]. In agreement with the data coming from the United 
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States, the total number of BC cases described in the litera-
ture in the age range 0-19 is limited to a few thousand pa-
tients, all-time and worldwide (Table 1). An extensive analy-
sis of all known cases of pediatric/teen malignant bladder 
masses [2] revealed that at least ten different types/subtypes 
of BC may be found for them, although with a rare or very 
rare incidence, in some cases (Table 1). 
 BC in children and teenagers resembles, for a few char-
acteristics, the same behavior of adult tumors. The first 
symptom usually is a painless macroscopic hematuria; simi-
larly to adults, males are more affected than females, and in 
some cases a genetic background and a relationship with 
specific chemicals and pollutants has been identified. How-
ever, many features of pediatric/teen BC are specific of this 
age range and suggest that this pathology is quite different 
from its adult counterpart. In particular, pediatric/teen BC is 
usually unifocal, while most adults have multifocal masses; 
most cases in this age range are of lower grade and stage 
(despite their delayed diagnosis, which is often due to being 
unexpected) and have an indolent behavior, thus granting 
these young patients a far more favorable prognosis and a 
recurrence rate much lower than in adults [16]. Genetic and 
genomic alterations frequently seen in older adults are ex-
tremely rare in young patients and, despite the constantly 
higher incidence in males, the male/female ratio is 
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Table 1. Reported pediatric and teenage patients with malignant bladder masses. 
Bladder Cancer Type/subtype 
Number of Cases Retrieved from 
the Literature 
Incidence On Total Bladder Cancers in Pediatric and 
Teenage Patients 
References 
rhabdomyosarcoma some thousands 
20% of all rhabdomyosarcomas, which are 4-8% of all malig-
nant pediatric tumors 
[3, 4] 
transitional cell carcinoma ca. 150 0.4% [5-7] 
leiomyosarcoma a few tens 0.1% [8] 
urachal adenocarcinoma a few tens 0.17%-0.34% [4, 9] 
adenocarcinoma of the exstrophied 
bladder 
less than 100 < 1/50,000 newborn with exstrophied bladder [10] 
inflammatory myofibroblastic tumor 36 < 0.1% [11] 
mesonephric and clear cell adeno-
carcinoma 
19 < 0.03% [12] 
perivascular epithelioid cell neo-
plasm 
1 extremely rare [13] 
paraganglioma/ pheochromocitoma 10 2/106 cases per year [14] 
pure malignant rhabdoid tumor 8 extremely rare [15] 
Column 1: bladder cancer type/subtype; column 2: number of cases described in the literature; column 3: incidence on total pediatric/teen bladder cases; column 4: references. Data 
were retrieved from [2] and integrated with the most recent bibliography available. Listed references refer to the primary or most relevant sources used for generating this table.
age-dependent, being greater at younger ages [2, 16, 17]. 
This led some Authors [17] to hypothesize the presence of an 
age-dependent threshold, set approximately at 19-20 years, 
which determines different properties in youngsters vs. 
adults. Along the same line of thought, other Authors sug-
gest that the management and treatment of young BC pa-
tients should be modified as well with respect to their adult 
counterparts; in particular, special attention should be used 
in preserving both the structural and functional physiology of 
patients (e.g. sexual functions in females, potency in males, 
fertility and urinary continence in both genders) [16]. 
 As a consequence of the low number of reported cases, 
the genetic analyses of pediatric and teen BC patients are 
even rarer. This is not a trivial problem since, as noted 
above, the phenotypic patterns of these malignancies are 
typically different from adults; thus, it is likely that also their 
overall genetic background is different. In this perspective, it 
would not be a surprise to find out that different sets of genes 
are involved in the same tumor, according to patient’s age, 
regardless of similar histological types, or even that some 
genes expressed in adult cancers are not involved in their 
pediatric/teen counterparts, and vice versa. Trying to find 
answers to these questions, we analyzed what is known 
about the BC genetics during childhood and adolescence; the 
21 genes examined in this article were clearly and univocally 
identified in patients with bladder neoplasms whose age was 
 19 years old. In this way, we were able to link the follow-
ing genes to BNPTP (note: p53, NF1 e SMARCB1 are re-
peated twice below, because they were identified using two 
different methods): i) CK20, p16/lnk4, SMARCB1, ALK, 
ACTA2, CD34, CD56, MUC1, p53, WT1, VIM and MYOG 
by immunohistochemistry; ii) H-RAS and NF1 by genetics, 
being the patient also affected by other known genetic dis-
eases, namely Costello syndrome and neurofibromatosis, 
respectively; iii) K-RAS, N-RAS, NF1, p53, PTPN11 and 
SMARCB1 by gene sequencing; iv) Gli1, Gli3, Myf5, 
MyoD1, Ptch1 by mRNA quantification (microarray analy-
sis).  
 Gene Ontology (GO) ‘is a community-based bioinfor-
matics resource that supplies information about gene product 
function using ontologies to represent biological knowledge’ 
[18]. GO-based computational tools, in particular, are used 
for performing analyses that allow determining which bio-
logical processes (BP), cellular components (CC) and mo-
lecular functions (MF) are most involved in a pathology, 
experimental condition, cellular response to stimuli, etc. [19, 
20]. We found that 75 GO-BP terms reach the statistical sig-
nificance for our list of genes; this number drops to 26 using 
a semantic similarity algorithm for redundancy reduction. 
The 26 GO-BP categories that are left after this filtering in-
volve: i) regulative processes (cell signaling, metabolism, 
matrix adhesion, intracellular transport, etc.) and ii) differen-
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tiation and development. Looking at the GO results from a 
different standpoint we were also able to distinguish GO 
terms that suggest similarities between adults and chil-
dren/teenagers (e.g. ‘positive regulation of nucleobase-
containing compound metabolism’ ‘regulation of intracellu-
lar transport’, ‘actin filament-based process’, and ‘cytoskele-
ton organization’) and others that seem to be peculiar of 
BNPTP (‘gland development’, ‘metanephros development’, 
‘striated muscle cell differentiation’, ‘regionalization’, ‘pat-
tern specification process’, and ‘embryonic morphogenesis’). 
 An assessment of possible biological events happening 
upstream of these 21 effector genes and of mechanisms ca-
pable to interfere with them with different modalities was 
performed i) evaluating which genes in this list are down-
stream of the 189 oncogenic signatures of the Molecular 
Signatures Database (OSMSD) and ii) checking if the nature 
of the perturbation of possible upstream genes that were 
found was compatible with the genomic perturbations de-
scribed in BNPTP. A standard and powerful use of these 189 
gene signatures is accomplished inside the Gene Set Enrich-
ment Analysis (GSEA) framework [21] or using other gene 
set-based tools [22-24]. Many publications based on GSEA 
and similar methods have proven that it is possible to use 
evidence derived by a broad spectrum of experiments (e.g. 
on human and murine models) and apply it to the analysis of 
two different groups of samples/patients [25-27]. This is an 
intrinsically noisy process that GSEA manages relying on 
the robustness of sets of genes, rather than single genes. 
Since we do not have, instead, any high-throughput data to 
start from and our only input is a list of deregulated/altered 
genes, we decided to rely on the strength of the inter-
experimental biological compatibility above described and 
accept a higher rate of false discoveries for each relevant 
case found in the hit matrix, which has 53 rows (gene sets), 
21 columns (BNPTP genes) and 60 hits (matches between a 
gene set and a BNPTP gene). A number of possibly impor-
tant upstream events were defined using this method, allow-
ing connecting the 21 genes that are altered in BNPTP with 
the regulation of (proto)oncogenes and (putative) tumor sup-
pressors, such as BRCA1, CCND1, RBBP8/CTIP, E2F3, 
ERBB2/HER2, WNT1, YAP1 and RB1-RBL2/p130 com-
bined (see the Results section). Despite the fact that TP53 
(a.k.a. tumor protein p53) is the most frequently mutated 
gene in BC specimens from adults [28], its status is not well-
defined in the only (teenage) patient reported with TP53 al-
terations [17] and our gene set-based analyses were not able 
to determine if and how much TP53 is important in pediatric 
and teenage BC cases. Notably, our results advocate for a 
role played by CTIP and WNT1, which instead do not seem 
to be involved as pivotal genes in BC of adults, as part of the 
oncogenic signaling pathways of BNPTP. 
2. MATERIALS AND METHODS 
2.1. Literature-based Gene Selection 
 The literature used for identifying BNPTP genes was 
selected using quite stringent criteria, since the analyses de-
scribed in this article are sensitive to the presence/absence of 
single genes in the final list. MEDLINE was accessed multi-
ple times, up to February 2015, and searched through the 
PubMed search engine using the strings “bladder cancer ge-
netics pediatric” (which retrieved 61 results), “bladder can-
cer gene pediatric” (54 results), “bladder cancer genetics 
child” (116 results), “bladder cancer gene children” (84 re-
sults), “bladder cancer gene child” (69 results) and “bladder 
cancer genetics children” (131 results). We chose the stan-
dard PubMed search and decided not to use MeSH terms and 
Boolean operators, in order to maximize the number of hits. 
The results were merged into one list and com-
pared/integrated with the references available from Vallas-
ciani and coworkers [2]. To expand the potentially suitable 
literature, also references cited in the manuscripts selected so 
far, but absent from our initially merged list, were checked, 
and the neoplastic alterations identified (such as “rhabdomy-
osarcoma”, “transitional cell carcinoma” and others similar) 
were used for further PubMed searches together with the 
keywords “bladder cancer” and either one of the following: 
“child”, “children” or “pediatric”. Any additional hit coming 
from this new search and not present in the former list was 
checked for its content. Then, all references were quality-
checked, and only those simultaneously fulfilling the follow-
ing three requirements were considered: (1) the gene had to 
be undoubtedly and univocally identified in the cancer 
specimen, either by (a) gene sequencing, (b) mRNA level 
quantification by microarray, (c) protein expression by im-
munohistochemistry (provided the absence of cross-
reactions) either using immunoblotting, or kinase assay, or 
indirect immunofluorescence on sample slides, or tissue mi-
croarray, or (d) analysis of chromosome rearrangements by 
FISH. For example, an article from Scott and collaborators 
[29] identified the over-expression of high molecular weight 
cytokeratins using monoclonal antibodies. However, an ac-
curate check of the same manuscript [29] and of the web site 
of the Company that sells this antibody [30] revealed that it 
recognizes at least four different cytokeratins, and for this 
reason this report was not used for our gene list. (2) Patient’s 
age had to be clearly indicated and not to be higher than 19 
years, or because stated for the patient(s), one by one, or 
because the age range reported was lower than 19 years old 
for all patients examined and unequivocally identified. 
Therefore, reports in which the age range was within our 
upper limit, even if single patients’ ages were not specified, 
met our selection criteria [31, 32]. (3) The primary tumor 
had to be localized in the bladder. This requirement pre-
vented us from using several contributions about the rhab-
domyosarcoma (RMS) genetics, since in many cases of pe-
diatric/teen reports the primary localization of this tumor is 
not described (RMS specimens are usually merged, irrespec-
tive of their explantation origin). For example, we were not 
able to find any paper describing the involvement - in blad-
der RMS - of the PAX-FOXO1 fusion gene, which is one of 
the most common genetic alterations found in RMS occur-
ring in other locations [33]. The final list of references that 
was used for the present report included 16 manuscripts pub-
lished between 1989 and 2014 (Table 2; references inside), 
allowing the identification of 21 genes.  
2.2. Gene Ontology (GO) Analysis 
 The 21 genes identified in the above screening were 
combined and a GO analysis was performed on them. In-
deed, while, as reported in Table 2, the nature of the altera-
tion and the gene status found for each are very different and
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IMT arr immunohistochemistry 14 male 36 105590 
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IMT arr immunohistochemistry 5 female 36 105590 
H-RAS HRAS GTPase oncogene carcinoma und Costello syndrome patient 12 male 37 190020 
K-RAS KRAS GTPase oncogene RMS mut K13Asp 4 female 38 190070 
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over immunohistochemistry 4 (e) female 45 158340
Column 1: gene names as reported in the manuscripts, which are listed in column 10; column 2: gene names according to the Molecular Signatures Database, which was used for 
performing the gene set-based analyses; column 3: main molecular function of the protein encoded by that gene; column 4: most relevant cellular function of this protein; column 5: 
neoplasm affecting the patient(s); column 6: molecular alteration, which is reported by or deduced from the bibliographic reference(s); column 7: in case of gene sequencing, the 
mutation is reported; in case of protein function analysis or mRNA quantification, the method used is reported; column 8: patient age; unspecified cases are patients that are surely 
under 19 years old, but whose exact age is unknown; column 9: patient sex; n/a means that this information is not available; column 10: reference(s); column 11: gene identification 
number inside the OMIM database (URL: www.ncbi.nlm.nih.gov/omim). Abbreviations: FISH – Fluorescent In Situ Hybridization; PUNLMP – Papillary Urothelial Neoplasm of 
Low Malignant Potential; CNS – Central Nervous System; RMS – rhabdomyosarcoma; IMT – inflammatory miofobroblastic tumor; mut – mutation, point mutation; over – overex-
pression; under – underexpression; del – deletion; arr – rearrangement; und – undefined mutation. Notes: (a) duplicate lines indicate different patients with mutations in the same 
gene; (b) age is expressed in years, unless where differently specified with an “m” next to the number, indicating “months”; (c) the same patient has both mutations; (d) all alterations 
belong to the same patient; (e) all alterations are referred to the same patient.
involve mRNA level, protein level or protein activity, both 
in terms of up- or down-regulation and detectable pres-
ence/absence, they all share the status of BNPTP biomarkers. 
Additionally, we assumed that the histological heterogeneity 
of tumors described was partially representative of the het-
erogeneity in the population and considered their aggrega-
tion as a balanced methodological choice, especially in the 
light of recent trends in medicine. As a matter of fact, our 
approach i) can be seen as more restrictive of the philosophy 
that inspires basket trials (for patients sharing some features, 
independently of their tumor histology) [46, 47], since we 
maintained the sharp boundaries of including only pediatric 
and teen BC and ii) is focused on sifting out the shared 
biological themes of malignancies that affect the bladder in 
pre-adults and not on defining biological processes that are 
specific of the single tumor entries of Tables 1 and 2. This 
GO analysis relies on the Expression Analysis Systematic 
Explorer (EASE) score (a p-value obtained through an 
adjusted Fisher’s exact test) [48] and was performed using 
DAVID Bioinformatics Resources [49]; the selected 
background was ‘Homo sapiens’. Each GO category was 
considered for further analyses only when fulfilling these 
three criteria: 1) is referred to biological processes (BP); 2) 
has two or more gene members inside the BNPTP gene list 
(Table S1); 3) has a p-value lower than 0.01 (Table 3). This 
third choice was made in order to collect GO-BP categories 
that account for at least 75% of the genes belonging to the 
original BNPTP gene list and to keep, among the statistically 
significant GO terms, > 33% of the GO categories that fulfil 
1) and 2). REVIGO [50] and Cytoscape [51] were 
respectively used for summarizing (reduction of the semantic 
redundancy of the GO terms) and visualizing the GO-BP 
results that comply with the three aforementioned criteria. 
The level of ‘allowed similarity’ was 0.5 (classified by the 
REVIGO developers as ‘small’), the selected species was 
‘small’), the selected species was ‘Homo sapiens’ and the 
chosen semantic similarity measure for assessing the dis-
tance between two GO terms was SimRel. SimRel is calcu-
lated from the directed acyclic graph (DAG) of the GO terms 
and, for each couple of GO categories, accounts for: i) the 
information content (IC) of their most informative common 
ancestors (MICA) in the graph; ii) the IC of the two catego-
ries that are compared; iii) the MICA probability of annota-
tion [52]. The REVIGO algorithm agglomerates GO terms 
and defines their level of dispensability through a procedure 
that is conceptually similar to a hierarchical clustering 
where, after calculating all the pairwise SimRel distances, 
GO terms are selected for the summarizing graph or dropped 
according to 1) their biological specificity, based on how 
many proteins they tag in the GO database (see below), 2) 
their p-values (previously calculated by DAVID), 3) the ex-
isting parent-child relationships in the GO-DAG [50]. Table 
S2 shows how much the GO-BP terms found using DAVID 
Bioinformatics Resources are dispensable in a scale from 0 
(100% indispensable) to 1 (100% dispensable). One of the 
output files generated by REVIGO was used as the input for 
creating a Cytoscape graph [51]; in this computational step, 
the European Molecular Biology Laboratory (EMBL) - 
European Bioinformatics Institute (EBI) GO Annotation 
(GOA) database is used for ultimately tagging the summariz-
ing GOs of the Cytoscape network [53, 54]. Using two dif-
ferent GO databases, one for assigning the p-values and one 
for selecting the most representative GO terms, slightly im-
proves the consistency of this process. Notably, while 
DAVID measures how relevant is the contribution of the 21 
BNPTP genes in each GO category, REVIGO defines topo-
logical relationships among the selected categories (in our 
case, 26) as a whole, i.e., without accounting for how many 
of the original BNPTP genes belong to them. In this way,
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Table 3. GO-BP terms selected by DAVID and having a p-value < 0.01. 
GO-Term Count p-value 
GO:0007569~cell aging 5 1.38E-07 
GO:0008542~visual learning 4 7.90E-06 
GO:0043523~regulation of neuron apoptosis 5 8.18E-06 
GO:0042127~regulation of cell proliferation 9 8.52E-06 
GO:0007632~visual behavior 4 1.21E-05 
GO:0035022~positive regulation of Rac protein signal transduction 3 1.24E-05 
GO:0007568~aging 5 1.81E-05 
GO:0045935~positive regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 8 1.97E-05 
GO:0051173~positive regulation of nitrogen compound metabolic process 8 2.41E-05 
GO:0010557~positive regulation of macromolecule biosynthetic process 8 2.67E-05 
GO:0031328~positive regulation of cellular biosynthetic process 8 3.59E-05 
GO:0009891~positive regulation of biosynthetic process 8 3.95E-05 
GO:0009416~response to light stimulus 5 4.42E-05 
GO:0046822~regulation of nucleocytoplasmic transport 4 8.10E-05 
GO:0007612~learning 4 8.96E-05 
GO:0045941~positive regulation of transcription 7 1.20E-04 
GO:0035020~regulation of Rac protein signal transduction 3 1.36E-04 
GO:0010628~positive regulation of gene expression 7 1.41E-04 
GO:0032386~regulation of intracellular transport 4 1.48E-04 
GO:0010604~positive regulation of macromolecule metabolic process 8 1.49E-04 
GO:0009628~response to abiotic stimulus 6 1.60E-04 
GO:0045944~positive regulation of transcription from RNA polymerase II promoter 6 1.67E-04 
GO:0009314~response to radiation 5 1.87E-04 
GO:0046579~positive regulation of Ras protein signal transduction 3 2.46E-04 
GO:0051057~positive regulation of small GTPase mediated signal transduction 3 2.79E-04 
GO:0032228~regulation of synaptic transmission, GABAergic 3 2.79E-04 
GO:0051146~striated muscle cell differentiation 4 2.80E-04 
GO:0007224~smoothened signaling pathway 3 3.50E-04 
GO:0060341~regulation of cellular localization 5 4.24E-04 
GO:0048169~regulation of long-term neuronal synaptic plasticity 3 4.29E-04 
GO:0007265~Ras protein signal transduction 4 4.71E-04 
GO:0045893~positive regulation of transcription, DNA-dependent 6 5.33E-04 
GO:0007611~learning or memory 4 5.54E-04 
GO:0051254~positive regulation of RNA metabolic process 6 5.54E-04 
GO:0051223~regulation of protein transport 4 5.98E-04 
GO:0070201~regulation of establishment of protein localization 4 7.12E-04 
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(Table 3) contd…. 
GO-Term Count p-value 
GO:0042692~muscle cell differentiation 4 7.12E-04 
GO:0001952~regulation of cell-matrix adhesion 3 7.13E-04 
GO:0009967~positive regulation of signal transduction 5 8.15E-04 
GO:0042981~regulation of apoptosis 7 8.16E-04 
GO:0043067~regulation of programmed cell death 7 8.60E-04 
GO:0010941~regulation of cell death 7 8.76E-04 
GO:0048598~embryonic morphogenesis 5 9.45E-04 
GO:0048732~gland development 4 9.78E-04 
GO:0032880~regulation of protein localization 4 0.001042703 
GO:0010647~positive regulation of cell communication 5 0.001222605 
GO:0048168~regulation of neuronal synaptic plasticity 3 0.001269391 
GO:0044093~positive regulation of molecular function 6 0.001351732 
GO:0040008~regulation of growth 5 0.001395832 
GO:0006915~apoptosis 6 0.001524138 
GO:0012501~programmed cell death 6 0.001628036 
GO:0008285~negative regulation of cell proliferation 5 0.001721827 
GO:0001656~metanephros development 3 0.001892643 
GO:0010810~regulation of cell-substrate adhesion 3 0.002067039 
GO:0043524~negative regulation of neuron apoptosis 3 0.002535107 
GO:0033157~regulation of intracellular protein transport 3 0.002735058 
GO:0003002~regionalization 4 0.002888256 
GO:0008219~cell death 6 0.003325104 
GO:0007010~cytoskeleton organization 5 0.003420399 
GO:0016265~death 6 0.003426397 
GO:0046578~regulation of Ras protein signal transduction 4 0.003459311 
GO:0006357~regulation of transcription from RNA polymerase II promoter 6 0.003488245 
GO:0009953~dorsal/ventral pattern formation 3 0.003491407 
GO:0006275~regulation of DNA replication 3 0.003723492 
GO:0048167~regulation of synaptic plasticity 3 0.003962608 
GO:0030036~actin cytoskeleton organization 4 0.004251627 
GO:0030029~actin filament-based process 4 0.005087539 
GO:0051056~regulation of small GTPase mediated signal transduction 4 0.005759671 
GO:0043085~positive regulation of catalytic activity 5 0.006401214 
GO:0007389~pattern specification process 4 0.006759105 
GO:0000075~cell cycle checkpoint 3 0.007859257 
GO:0001822~kidney development 3 0.00871315 
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(Table 3) contd…. 
GO-Term Count p-value 
GO:0007406~negative regulation of neuroblast proliferation 2 0.008839397 
GO:0007264~small GTPase mediated signal transduction 4 0.009734957 
GO:0051090~regulation of transcription factor activity 3 0.009975498 
Column 1: 75 GO-Terms (GO code and GO category name); column 2: number of genes of BNPTP that are found inside that GO category; column 3: p-value.
our approach considers the role played by a GO category as a 
working hypothesis and displays its semantic similarity net-
work as if that GO category was fully involved in the BPs of 
these malignant neoplasms. 
2.3. Identification of Possible Upstream Inducers and 
Additive/synergistic Effects Using Oncogenic Signatures 
 The 189 gene sets (oncogenic signatures) that were used 
for these analyses were obtained from the Molecular Signa-
tures Database of the Broad Institute. One of their main uses 
has been comparing two groups of samples and determining 
if the expression values of the genes that belong to each gene 
set suggest that in either group those genes have significantly 
higher expression values (this is called ‘enrichment’), using 
a Kolmogorov-Smirnov-like statistic [21]. In our analysis, 
instead, the occurrences of the 21 BNPTP genes in the 
OSMSD are calculated running an in-house developed 
MATLAB [55] script, thus obtaining a binary matrix M (mi,j
= 1 when the gene j is found in the gene set i (this is called a 
‘hit’) and 0 otherwise). For the sake of brevity, M is named 
hit matrix and when in the text we comment the existence of 
a match between a gene set and a gene, we use phrases such 
as “the gene X is hit by the gene set Y”, “the gene set Y is 
hit by the gene X”, etc. Also for short we use phrases such as 
“pro-growth”, “anti-growth”, “pro-proliferative”, “anti-
proliferative”, and similar expressions, for the gene sets, 
which are far from fully depicting the complexity of the ex-
periments performed for defining them, but are supposed to 
help the [56] Reader to quickly determine the biological 
background and/or polarity of what is shown.  
 Remarkably, the 21 genes altered in BNPTP have differ-
ent cell functions: beside oncogenes and tumor suppressors, 
there are cytoskeleton components, cell-cell adhesion fac-
tors, and so on (Table 2). Therefore, looking for matches in 
the hit matrix can be seen as a convenient strategy of back-
tracking, which allows shifting the analysis focus from the 
identified BNPTP genes to potential (and not yet identified) 
inducers/co-regulators that mostly belong to the families of 
oncogenes and tumor suppressors. We want to specify that 
from here to the end of this article the words oncogenes, tu-
mor suppressors and similar may be loosely used, for short. 
Indeed, for the sake of our evaluations, a gene officially clas-
sified as an oncogene or a gene able to promote cell cycle 
progression, cell growth, and comparable/related biological 
processes, merge into the same experimental gene group; 
similarly for tumor suppressors vs. anti-proliferative, pro-
apoptotic or likewise defined genes. However, this descrip-
tive style is applied only to groups of genes; instead, when a 
statement is made about a specific gene, it is defined and 
referenced as accurately as we deemed necessary. After find-
ing all the gene hits, a spreadsheet was generated, aiming at 
summarizing and displaying in a user-friendly way the avail-
able data. The matrix columns were annotated with informa-
tion about the 21 genes, using the following fields: 1) gene 
alteration, 2) description of the experimental evidence, 3) 
number of patients on which those data are based (that we 
also relate to the degree of reliability of that gene), and 4) 
putative activity type (Table 4). Additionally, each gene set 
was annotated with information found in the on-line OSMSD 
resources, using the following five fields: 1) brief description 
(it summarizes the experiment performed), 2) full description 
or abstract (it explains more in detail the experiment or has 
an excerpt from the article’s abstract), 3) source publication 
(it displays the reference article or the Authors), 4) exact 
source (it describes the experimental comparison and the 
level of stringency used), and 5) organism (it shows if the 
cell line used was human or murine) (Table S3). We are 
aware that the style and content of these five fields would 
need improvement, and we have also noticed mistakes in this 
annotation. Nevertheless, since the incomplete or wrong an-
notation of OSMSD did not interfere with our analyses and 
we have amended and edited what was needed in the main 
text, we have left, for consistency, the information of Table 3
as it can be found in the Molecular Signatures Database. 
There are two data features that increase the reliability of this 
type of analysis: a) all the OSMSD have a number of mem-
bers  481 (NFE2L2.V2) and, in the case of the 53 gene sets 
used for this analysis,  294 (STK33_NOMO_UP) (Table 
S4). This stringent selection of candidates, based on gene 
sets having relatively small sizes, reduces the risk that hits 
within a gene set happen by pure chance; b) all found 
matches are shown in Table 4, so that Readers can formulate 
hypotheses on their own about the meaning of these hits. 
However, in order to further increase the reliability of the as-
sessments made in the Results, we decided to disregard those 
gene sets that do not comply with each of these three criteria: 
(i) the experimental procedures, reported in the manuscript 
that was used for defining the gene set (Table S3, column 4), 
allow estimating/determining the type and effect of the ex-
perimental stimulus; (ii) there is a good degree of biological 
consistency between BNPTP and the biological system or the 
cells (either transformed or normal) used in the gene set ex-
perimental procedure. Alternatively, the cell lines can be re-
garded, in our judgement or according to the literature, as re-
cipient/model cells of general biological relevance where spe-
cific biochemical events are induced and/or tested. A third 
case is that the gene targeted by the gene set experiment is 
tested in what seems to be a cell line-specific background, but 
there is enough evidence that the same gene is important for a 
spectrum of cancer types or biological phenomena that goes 
beyond the disease typically modeled by that cell line. 
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When this last case is applied, we explain in the text the bio-
logical implications of this inclusion (this is what we did for 
some gene sets identified using leukemia cell lines); (iii) it is 
possible to determine a specific or non-specific gene/protein 
targeted by the methods used to induce/inhibit cell growth, 
using both the Authors’ description and the OSMSD annota-
tion; for example, in some experiments cells were treated 
with growth factors, but the identification of the proteins, 
which are up- or down- regulated, was not performed or was 
not clearly enough explained (similarly for cells that are 
slowed down). The gene sets marked with an X in Table S3,
column 7, include either those obtained through the down-
regulation of a (putative) tumor suppressor, or those gener-
ated through the upregulation/downregulation of a 
(proto)oncogene. The downregulation was achieved in 
knock-out mice (RB_P130_DN.V1_UP) or by RNA-
interference (ATM_DN.V1_DN, BMI1_DN.V1_UP, BRC 
A1_DN.V1_UP, CTIP_DN.V1_UP, HOXA9_DN.V1_UP, 
P53_DN.V2_DN, P53_DN.V2_UP, PTEN_DN.V1_DN, 
STK33_NOMO_UP, STK33_SKM_UP, TBK1.DF_DN, 
TBK1.DN.48HRS_UP); since these techniques are reported 
to have a high efficiency, we confidently assumed that the 
target gene/protein has a residual activity close to zero. The 
upregulation was mostly obtained by overexpressing a trans-
gene using a suitable vector (such as a virus); other tech-
niques include adding a chemical compound targeting a spe-
cific protein (ERB2_UP.V1_UP, NOTCH_DN.V1_UP, 
WNT_UP.V1_DN, WNT_UP.V1_UP) or achieving gene 
amplification (YAP1_UP). In most cases, the exact amount 
of upregulation is not quantified (either in terms of cell pro-
liferation or in terms of concentration/activity of the intracel-
lular protein), but we conventionally considered these gene 
sets as reliable as those based on knock-out mice and RNA-
interference, since the described techniques and reagents are 
largely used in the field and show consistent and reproduci-
ble results [57]. 
 Gene sets that do not fulfil the above criteria (26 out of 
53) were candidates for exclusion (CFE) from the Results. 
Overall, gene sets were CFE because: i) we deemed the tis-
sue of origin of these cells not informative enough for mak-
ing inferences on pediatric/teenage BC and this feature was 
not balanced by the cell line being considered a model of 
general relevance (ATF2_S_UP.V1_DN derived from myo-
metrium; CAHOY_ASTROGLIAL derived from astroglia 
cells; ESC_J1_UP_LATE.V1_DN, ESC_V6.5_UP_ 
EARLY.V1_UP and ESC_V6.5_UP_LATE.V1_DN based 
on embryoid bodies; PIGF_UP.V1_DN and VEGF_A_UP. 
V1_UP based on human umbilical cord vein endothelial 
cells, JAK2_DN.V1_UP of erythroleukemia cells), ii) the 
target gene alteration was not sufficiently described, either as 
a mutation of DNA or of the protein sequence or for the ef-
fects induced on the protein function (P53_DN.V1_DN and 
P53_DN.V1_UP), iii) the effect of gene silencing/ upregula-
tion is not sufficiently clear in tumorigenesis or has not been 
exhaustively stated in the relevant manuscript 
(PRC2_EDD_UP.V1_UP was discarded because the role of 
the EED gene (a transcriptional repressor, member of the 
Polycomb group) in oncogenesis is currently unclear and the 
only mutation in man described so far [58] causes a Weaver-
like syndrome, characterized by overgrowth but not cancer; 
RPS14_DN.V1_UP was discarded because RPS14 encodes a 
ribosomal protein part of the 40S subunit of the ribosome: its 
impairment has a general role on protein biosynthesis, but 
not a “specific” role in carcinogenesis), iv) the cells were 
forced to differentiate (LEF1_UP.V1_DN and LEF1_ 
UP.V1_UP, where an epithelial to mesenchymal transition 
(EMT) is induced), v) the cells were treated with growth 
enhancers or inhibitors having a generic effect on cell prolif-
eration without describing the main genetic targets related to 
tumorigenesis (CSR_LATE_UP.V1_DN, DCA_UP.V1_DN, 
GCNP_SHH_UP_LATE.V1_UP, IL15_UP.V1_UP, IL2_ 
UP.V1_DN, IL2_UP.V1_UP, IL21_UP.V1_UP, PDGF_ 
UP.V1_DN, PDGF_UP.V1_UP, RAPA_EARLY_UP.V1_ 
DN and TGFB_UP.V1_DN), vi) the definition of the gene 
set in the OSMSD is ambiguous and, most likely, the in-
duced effect is not specific enough (LTE2_UP.V1_UP). 
 Finally, we decided to partially overrule the aforemen-
tioned selection criteria by including in the final analyses the 
two gene sets concerning TP53 that were excluded so far 
(i.e., P53_DN.V1_DN and P53_DN.V1_UP) because of the 
importance of this tumor suppressor and of some general 
evaluations about how these two gene sets were generated. 
Specifically, the NCI-60 panel of cell lines was screened and 
two cell line groups were created for TP53: a) 17 carrying a 
normal p53; b) 33 with a mutant p53 [21]. Generally speak-
ing, it is true that i) each different mutant of p53 behaves 
differently, ii) some of them exhibit gain of function (en-
hanced tumorigenicity and resistance to therapy) and others 
do not [59, 60], and iii) it is challenging to interpret results of 
a direct comparison between these two groups, since they 
were created by combining all the mutants. However, it is 
also true that these two gene sets are based on the presence 
of mutant p53, so on conditions that, more or less effec-
tively, promote cell proliferation. The “rescue” of these two 
cases brings the final count of gene sets for this article to 29 
used and 24 discarded from the analysis. 
2.4. Standardized Criteria for Commenting the Matrix 
Hits 
 Each hit of this matrix has been evaluated in the follow-
ing sequential way. Step 1: assuming that the background of 
BNPTP is constantly pro-growth (all being cancer patients), 
the background of the experiment that generated each gene 
set is assessed, thus allowing splitting the 29 gene sets that 
successfully went through the steps above into “generated in 
pro-growth conditions” and “generated in anti-growth condi-
tions”. Step 2: it is checked if the polarity of the gene set 
(containing genes upregulated or downregulated) matches 
the polarity of the activity type of the BNPTP genes (also 
upregulated or downregulated). BNPTP genes that are con-
flicting or undefined are sometimes commented in the Re-
sults, but we do not consider them as part of our core as-
sessments. Step 3: combining background and polarity, it is 
possible to generate standard comments, which are based on 
the assumption that 16 cases are overall possible. Indeed, in 
a very simplified perspective, the experimental input can 
determine activation or repression of an oncogene or a tumor 
suppressor (total: four cases possible). Additionally, the gene 
set typology is UP or DOWN and the same happens for each 
BNPTP (UP or DOWN) (total: four cases possible). The 
combination of the former and latter four cases defines the 
16 (= 4 x 4) instances mentioned before. Notably, these vari-
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ables allow also splitting the 16 cases into two groups with 8 
instances each, due to the fact that in half of the cases the 
biological background produced for the gene set is pro-
growth and in the other half is anti-growth; this means that in 
50% of the cases there is compatibility between BNPTP and 
gene set biological background and in the other 50% there is, 
instead, incompatibility. Of course, these cases are a priori 
defined and have nothing to do with how many actual 
matches we found for each of these 16 cases. In fact, there is 
an evident bias in the sort of experiments performed for de-
termining the gene sets (mostly pro-growth) as well as in the 
type of activity found for each BNPTP gene (mostly UP). 
Finally, when these analyses allow identifying a possible 
gene pathway of BNPTP, rather than a single upstream gene, 
up- and down- stream genes are connected, in the text, using 
a ; instead, the up- and down- regulation symbols are, re-
spectively,  and .
2.5. Gene Identification 
 Considering that multiple gene names are used in the 
literature for the same DNA sequence, all genes analyzed in 
the Results are uniquely identified through the Online Men-
delian Inheritance in Man (OMIM; http://www.omim.org) 
database identification (ID) number. This ID is reported in 
Table 2, column 11 (for the genes altered in BNPTP) and in 
the main text (for the genes that were targeted by the ex-
periments that allowed defining the gene sets collected in the 
Molecular Signatures Database). 
3. RESULTS 
3.1. Gene Ontology 
 We analyzed the 21 genes that have been found altered in 
BNPTP using methods based on gene ontology (GO), which 
is largely applied to genomics data [20, 61, 62]. We chose an 
exploratory point of view [63], trying to understand the col-
lective properties of these genes as much as possible, while 
deemphasizing the importance of the p-values obtained for 
each GO term, since these measures might be affected by the 
small number of genes available. In particular, we i) only 
looked for the most relevant GO terms of biological proc-
esses (BP), thus excluding GO terms related either to cellular 
component (CC) or molecular function (MF), ii) took into 
account, for our assessments, that some BPs are found be-
cause of the original bias of starting from a gene list, which 
contains cancer-related genes, iii) tried to determine if statis-
tically significant BPs that are apparently unrelated to 
BNPTP suggested the involvement of relevant, but elusive 
mechanisms, iv) used the evidence provided by the GO 
analyses for connecting the identified BPs and important 
mechanisms and molecules that have been described in BC, 
and v) minimized the number of GO-BP categories to be 
discussed using a measure of semantic similarity within an 
agglomerative process, which is conceptually similar to a 
hierarchical clustering applied to GO terms [50, 52]; this 
makes possible selecting redundant and non-redundant GO 
terms and allows reducing the complexity of the GO-BP 
graph. 
 The GO-BP summarizing graph (Fig. 1) shows two main 
subgraphs (left, with 9 nodes and right, with 11 nodes), two 
nodes linked to the node ‘small GTPase mediated signal 
transduction’, which belongs to the right subgraph, and 4 
isolated nodes, which we positioned at the bottom, on the left 
side of this graph. The left subgraph has stronger semantic 
connections (displayed as thicker edges, on average) among 
its nodes, when compared to the right subgraph. The right 
subgraph mainly contains terms related to regulatory mecha-
nisms, cellular organization and replication; three isolated 
Fig. (1). Main GO categories selected by REVIGO. The DAVID-derived p-values are used for determining the red color shading of the 
ovals (the darker the red, the more statistically significant the GO (see Table 3)). The edge thickness is proportional to the level of semantic 
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nodes (i.e., ‘regulation of growth’, ‘cell cycle checkpoint’ 
and ‘death’) are fully or partially related to cell replication as 
well. Some prominent GO terms of the right subgraph that 
are expected to be deregulated in cancer cells are: ‘regulation 
of DNA replication’, ‘regulation of cell proliferation’ and 
‘smoothened signaling pathway’. From a complementary 
perspective, four nodes on the right are related to cell-cell 
communication (‘regulation of cell-matrix adhesion’) and 
signal transduction (‘small GTPase mediated signal trans-
duction’, ‘positive regulation of Rac protein signal transduc-
tion’ and ‘positive regulation of nucleobase-containing com-
pound metabolism’). The GO term ‘small GTPase mediated 
signal transduction’ contains the protein NF1 and the three 
main members of the Ras subfamily (HRAS, KRAS and 
NRAS) (Tables 3 and S1), which are mutated and/or deregu-
lated in BNPTP. Overall, up to almost 30% of all human 
tumors screened - independently of tissue origin - present 
some mutation in any of the RAS genes, especially KRAS 
[64]. Approximately 13% of the BC specimens has a muta-
tion in one of the RAS proteins [65] and this is particularly 
true for the non-muscle invasive BC in adults [66]. Due to 
the chemical nature of GTPases, which hydrolyze guanosine 
triphosphate (GTP), it is very interesting finding the category 
‘positive regulation of nucleobase-containing compound
metabolism’. Indeed, beyond the direct role of GTP, also 
nucleotide-derived cyclic compounds seem to play a central 
role in the urogenital cancer development [67] and our GO 
analysis allows highlighting the importance of these biologi-
cal processes in BNPTP. Notably, at least some inhibitors of 
phosphodiesterases (PDEs) - which are critical components 
in the cyclic AMP/protein kinase A (PKA) and cyclic 
GMP/phosphokinase G (PKG) signaling pathways - are able 
to induce apoptosis and inhibit cell growth in rodent models 
of bladder cancer; additionally, one bladder cancer cell line 
(HT1376) derived from a woman [68] shows the overexpres-
sion of PDE5, similarly to human squamous and transitional 
cell carcinomas, when compared with normal urothelium 
[69]. Therefore, this last GO-BP term suggests that these 
biochemical events may be involved not only in adult BC but 
also in BNPTP. 
 It is crucial for a cell to segregate DNA and cytoplasm to 
the daughter cells, functionally using its molecular mecha-
nisms of cell division. Indeed, genes impairing the normal 
progression of cytokinesis are either down- or up- regulated 
in human cancers, according to their cellular role; addition-
ally, some of them have been mapped to chromosomal re-
gions that are either deleted or amplified in tumors or tumor-
derived cell lines [70-73]. GO terms such as ‘regulation of 
intracellular transport’ (inside the right subgraph), ‘actin 
filament-based process’ and ‘cytoskeleton organization’ 
(outside the right subgraph) fit quite well in these processes. 
Human genes causing cytokinesis failure have been involved 
in cancer pathogenesis [74, 75], inducing the formation of 
polyploid cells with an abnormal growth. In particular, this is 
true for bladder cancer [76]. Aneuploidy may be a conse-
quence, among other possibilities, of the centrosome func-
tion impairment. Indeed, it has been demonstrated that, in 
some BC specimens, mitotic kinases, such as Aurora A, are 
significantly overexpressed or amplified [77], and may in-
duce defective centrosome behavior as well as polyploidy 
[78, 79]. Similarly concerning the intracellular movement, 
but also cell-cell communication processes, there is the 
‘regulation of synaptic transmission GABAergic’, despite its 
role is usually related to the normal function of the nervous 
system (which here relies also on the GO term ‘regulation of 
neuron apoptotic process’). Notwithstanding the absence of a 
direct link between bladder cancer and vesicle movement in 
the literature, a hypothetical link may be defined. The correct 
course of cytokinesis involves the addition of membrane to 
the cleavage site, to allow furrow ingression and cytodiere-
sis. These phenomena occur through the movement of lipidic 
vesicles originating from the endoplasmic reticulum and 
modified in the Golgi stacks; failure of this intracellular 
transport causes cytokinesis impairment in animal models 
[80]. The parallel between this vesicle movement inside the 
cell and that of synaptic vesicles is quite straightforward, 
thus it is tempting to hypothesize that at least some molecu-
lar mechanisms are in common between these two biological 
phenomena. Altogether, nodes described so far (both inside 
the right subgraph and isolated) create a coherent picture of a 
general deregulation at the cellular level, as it is expected 
from specimens of cancer patients. 
 The left subgraph is somehow less expected, though; its 
nine nodes have thicker lines than the nodes in the other 
subgraph (Fig. 1), suggesting that their semantic connections 
are more intimate. If we consider the whole group of nodes, 
a relationship emerges between most of the GO terms identi-
fied and various processes of embryogenesis and/or devel-
opment. Six of these nodes are indeed involved in organo-
genesis (‘gland development’, ‘metanephros development’), 
tissue differentiation (‘striated muscle cell differentiation’) 
or body patterning (‘regionalization’, ‘pattern specification 
process’, ‘embryonic morphogenesis’). Two nodes of the left 
subgraph (‘aging’ and ‘cell aging’) are not apparently related 
to these processes, although it is fascinating to note that they 
may be considered as opposing the natural, embryonic re-
lated cellular rejuvenation [81, 82]. 
 The only apparently off-topic nodes of (Fig. 1) seem to 
be ‘visual learning’ (inside the left subgraph) and ‘response 
to abiotic stimulus’ (linked only to the node ‘small GTPase 
mediated signal transduction’). The definition of the former 
is “any process in an organism in which a change in behavior 
of an individual occurs in response to repeated exposure to a 
visual cue”; the definition of the latter is “any process that 
results in a change in state or activity of a cell or an organ-
ism (in terms of movement, secretion, enzyme production, 
gene expression, etc.) as a result of an abiotic (non-living) 
stimulus” [83]. Consequently, these two GO terms do share 
logical connections, being light an abiotic stimulus and a 
visual cue. As a matter of fact, the link between cyclic 
rhythms (which depend on the alternation of light and dark-
ness) and human diseases (including cancer) or health issues 
is not a novelty and has been investigated by chronobiology 
[84, 85]. Even the young age of the patients that are the fo-
cus of our analyses does not seem to be a limitation, except 
possibly for the youngest cases (see, for instance, Table 2,
row 27), since the emergence of important biological 
rhythms has been shown within 18 weeks from birth [86]. 
One of the genes involved in circadian cycles is TP53 [85, 
87, 88], which is present in the list of genes that are altered 
in BNPTP, although without a well-defined status (Table 2). 
This gene belongs to GO:0009416, ‘response to light stimu-
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lus’ (Tables S1 and S2), which is one of the five GO terms 
(out of the 75 identified using EASE) that depend on ‘visual 
learning’. Additionally, melatonin ‘is a chemical signal of 
darkness’ [89] that has also been used for treating cancer 
patients [90, 91]; melatonin receptors MT1 and MT2 are G-
protein coupled receptors that are expressed in various parts 
of the body, including the bladder [92]. The physiological 
changes induced by melatonin [92], the role of melatonin 
levels in aging [93] and apoptosis [94] and, more specifi-
cally, the direct effect of night work on bladder cancer for-
mation in adults [95] as well as the bladder role in the excre-
tion of melatonin metabolites at night [94] suggest that the 
relationships between the genes that belong to the ‘visual 
learning’ GO category and melatonin might play some role 
in BNPTP. Finally, if we refer to generic stimuli, any non-
endogenous chemical might be involved in the category ‘re-
sponse to abiotic stimulus’. Indeed, it is generally accepted 
that some chemicals influence the health of the inner bladder 
walls, since this tissue comes into contact with any hydro-
soluble compound waiting to be excreted in the urine. As a 
matter of fact, some substances – mostly pollutants – are 
directly or indirectly linked to bladder cancer formation in 
adults [65]. However, the contact between compounds and 
bladder walls usually requires many years to induce the neo-
plastic transformation [96], thus this situation is not easily 
applicable to pediatric/teen patients, even conceding that 
such substances might enter into contact with the fetus of a 
pregnant mother. For example, in adults the risk of BC is 
directly proportional to the number of years spent smoking 
and the exposure to occupational chemicals may cause BC 
after several decades. Also, hairdressers who performed their 
jobs for more than 10 years have a five-fold increase of their 
risk of being diagnosed with BC, while the hazard increases 
by 3.3 times for people who use permanent hair dyes at least 
once a month for 15 and more years [96]. Overall, in adults 
the BC incidence increases with age, being most commonly 
diagnosed in the seventh decade of life [97]. Altogether, data 
suggest that environmental factors per se (without a genetic 
predisposition) are not compatible with BC formation in in-
fants and are weakly correlated with BC in teenagers; how-
ever, it is evident that the time between first exposure and 
BC diagnosis is highly variable, probably depending on the 
stimulus (quality, quantity) and on the individual susceptibil-
ity. This quantitative topic deserves, in our opinion, to be 
investigated further.  
3.2. Gene Set Analysis and Identification of Possible Up-
stream Genomic Events 
 There is an urgent need to formulate hypotheses that, 
even if partially destined to not be confirmed experimentally, 
may help us understanding what happens, at a molecular 
level, when genes are altered (at the level of DNA, mRNA or 
protein) in BNPTP. In order to increase the chances to find 
relevant upstream events, either in etiological terms or as 
parallel biochemical events that target these effector genes, 
we limited our analysis to gene sets having an oncological 
relevance, which were described in biological contexts gen-
erally compatible with BNPTP (thus raising the conditional 
probability of finding successful matches). It is important to 
highlight that, since the average size (i.e., number of member 
genes) of the 189 oncological gene sets that were used is 
165.71 (Table S4), the average probability for a gene to be in 
a gene set by pure chance, looking at each gene set individu-
ally, is in the order of 1%. While a match between gene 
names in the BNPTP gene list and among the gene sets of 
oncological relevance is defined by a binary answer (namely, 
“yes, it belongs to” or “no, it is not found in”), the same is 
not true in terms of biological compatibility between a) ex-
perimental input and model system used for defining the 
gene set and b) nature of the alteration(s) found in the 
BNPTP genes. For this reason, while we have found 60 hits 
in the 53 x 21 matching matrix, the cases actually discussed 
below are only 34; indeed, our comments are limited to the 
most straightforward matches found and the other gene sets 
are left to the interpretation of the Readers. The gene de-
scriptions provided below, at the beginning of each gene 
paragraph, are intended as i) helpful information to be used 
by the Reader when checking the hits of Table 4 and the 
supplementary data of individual gene sets contained in  
Table S3 and ii) part of the contextualization approach fol-
lowed throughout the entire article, since we highlight gene 
features and molecular mechanisms that are mostly related 
with cell cycle progression and oncogenesis. The second half 
of each gene paragraph, instead, is part of the Results section 
in the most usual way and conceptually depends on the last 
three paragraphs of the Materials and Methods section. Since 
the analyses reported below are intended for the tumor sam-
ples in which these gene alterations were found in BNPTP, 
we suggest reading this section on a gene by gene basis and 
using all the information reported in Table 2.
3.2.1. ACTA2 
 Alpha-actin-2 (ACTA2) is one of six different actin iso-
forms which have been identified in vertebrates; in particu-
lar, this actin is present in the human aortic smooth muscle. 
In the aorta, ACTA2 interacts with the beta-myosin heavy 
chain MYH11 [98]. Recently, some links between ACTA2 
and cancer have been found: ACTA2 regulates c-MET and 
FAK expression in lung adenocarcinoma cells, which posi-
tively and selectively influence the metastatic potential [99]. 
Moreover, the acquisition of ACTA2 expression in the sar-
comatous component suggests that an EMT had occurred in 
the progression to metaplastic breast carcinoma [100]. Inter-
estingly, human malignant melanoma cells release a platelet-
derived growth factor-like substance that inhibits the expres-
sion of this gene in normal cells [101]. 
 The existing match between this gene and the gene set 
BMI1_DN.V1_UP [102], based on the silencing of the on-
cogene BMI1 (OMIM ID: 164831), establishes a link be-
tween the anti-growth condition of this gene set and the tu-
mor status of the patient who had an over-expression of the 
ACTA2 protein (detected by immunohistochemistry). Since 
the gene set is UP and the gene type is UP too, this match 
happens in conflicting experimental/clinical conditions. An 
analogous case happens for the gene set HOXA9_DN.V1_ 
UP [103], generated by silencing HOXA9 (OMIM ID: 
142956), which might be relevant for its function in sustain-
ing the cell proliferation rate [104], again with an UP/UP 
polarity for the gene set and this BNPTP gene in the pres-
ence of a discordant biological background. The experiment 
that defined this gene set was performed in acute myeloid 
leukemia (AML) cells, but since HOXA9 is important in 
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many cancers [105], we decided to comment this hit as a 
viable one. This gene is also hit by STK33_SKM_UP [106], 
which was defined upon silencing of STK33 (OMIM ID: 
607670) in mutant-KRAS cells. The precise molecular func-
tions and role of STK33 in these cells is debated [106-109]; 
however, as far as it is relevant for our analyses, since this 
gene set was derived in pro-apoptotic conditions and there is 
an UP/UP polarity for the couple gene set 
STK33_SKM_UP/gene ACTA2, this is another clear case of 
two conflicting biological conditions where this gene is 
upregulated. Finally, ACTA2 belongs to the gene set 
P53_DN.V1_DN (mutant p53, pro-proliferative conditions) 
[21], a gene set that collects genes that are down-regulated in 
the presence of a mutated p53 (OMIM ID: 191170). In this 
last case, we have compatibility between the experimental 
conditions, but a conflict at the level of gene response 
(DOWN for the gene set and UP for ACTA2). Altogether, 
these results suggest that the actual upregulation of the 
ACTA2 protein should be reevaluated, also considering that 
this evidence is limited to one patient, in order to assess the 
possibility to correct its “polarity” (i.e., from UP to DOWN) 
or, possibly, to understand if these conflicts between gene 
sets and status in BNPTP depend on tissue-specificity and/or 
the peculiar role played by ACTA2 in these malignancies. 
Notably, with a change of the ACTA2 “polarity” the first 
three gene sets aforementioned would suggest that ACTA2 is 
a critical gene for BNPTP, whose levels go down or up in 
pro- or anti- proliferative conditions, respectively. 
3.2.2. ALK 
 The anaplastic lymphoma kinase (ALK) is a receptor 
tyrosine kinase having a putative transmembrane domain and 
both an extracellular (N-terminal) and an intracellular (C-
terminal) domain; the kinase activity of ALK resides com-
pletely in the intracellular portion of the protein [110]. Its 
misexpression, consequent to an amplified, mutated, trun-
cated or rearranged protein, may lead to malignant transfor-
mation; mutations causing ALK kinase function hyperactiva-
tion, or putting the catalytic region under the control of an-
other genetic promoter (as in chromosome translocations) 
deregulate the enzyme that, in turn, phosphorylates its targets 
in aberrant times and/or tissues [110]. One of the manu-
scripts listed in Table 2 reports two pediatric/teen BC involv-
ing ALK rearrangements [36]. The Authors took advantage 
of two DNA probes (orange and green) encompassing the 
ALK locus, so that they are next to each other in normal 
cells; since in these two patients the green and orange stain-
ing were separated on two different chromosomes in cancer 
cells, they postulated an ALK rearrangement. Although the 
fusion partner is not described in this manuscript, in consid-
eration of the nature of the sample (a cancer specimen) and 
of ALK behavior in known fusion proteins in inflammatory 
myofibroblastic tumors ([36] and references therein), we 
assumed that also in these patients there was an upregulation 
of the activity of the ALK kinase fragment. 
 ALK belongs to the gene set RB_P130_DN.V1_UP 
[111] and its activity is UP in BNPTP. Since this gene set 
contains genes that are upregulated in the presence of a dou-
ble knock-out for RB1 (OMIM ID: 614041) [112] and RBL2 
(a.k.a. p130) (OMIM ID: 180203) [113, 114], any mecha-
nism that interferes with the function of these two (putative) 
tumor suppressors, whose cellular roles are partially over-
lapped [115], has the potential to worsen this phenotype. 
ALK is also hit by CYCLIN_D1_KE_.V1_DN [116], a gene 
set based on the overexpression of the putative oncogene 
CCND1 (a.k.a. cyclin D1) (OMIM ID: 168461). While there 
is compatibility between gene set and gene biological con-
text (i.e., they are both based on pro-proliferative condi-
tions), the fact that ALK mRNA is downregulated in the 
gene set and the ALK protein activity is instead upregulated 
in BNPTP does not provide a direct link between these two 
molecular events. 
3.2.3. CD34 
 The hematopoietic progenitor cell antigen, cluster of dif-
ferentiation 34 (CD34) is a cell surface glycoprotein that 
functions as a cell-cell adhesion factor. It is a transmembrane 
sialomucin protein expressed on early hematopoietic and 
vascular-associated tissue [117]. Although its function is still 
elusive, data collected suggest that it may be involved in cell 
morphogenesis and migration, enhanced proliferation, and 
block of cell differentiation [117]. Interestingly, the up-
regulation of the closely-related podocalyxin (member of the 
CD34 family of proteins) has been related to several malig-
nancies, including breast cancer, prostate cancer, embryonic 
carcinomas, leukemia and pancreatic cancer [117]. 
 For CD34 we have one of the most interesting cases of 
Table 4. Indeed, the gene set BRCA1_DN.V1_UP [118] hits 
this gene and this happens in pro-growth conditions for the 
experiment defining this gene set (silencing of BRCA1 
(OMIM ID: 113705)). Therefore there are good chances or 
that CD34 is downstream of BRCA1 and the deregulation of 
this tumor suppressor is critical for the onset of BC in young 
patients or that the status of BRCA1 may be critical for the 
progression of this type of cancer, being able to further sus-
tain the upregulation of this protein. Notably, a similar rela-
tionship can be established about the gene set 
CTIP_DN.V1_UP [118], which is based on the silencing of 
the tumor suppressor CtIP (a.k.a. RBBP8 or CTIP) (OMIM 
ID: 604124), whose association and interaction with BRCA1 
has been described [119]. Overall, this analysis shows that 
there are two tumor suppressors, i.e., BRCA1 and CtIP, 
whose silencing induces the transcription of the CD34 gene 
and in pediatric/teen BC this protein is indeed up-regulated. 
These experimental evidences deserve further research, look-
ing for cause-effect relationships between BRCA1/CTIP 
deregulation and upregulation of CD34 in BNPTP. Addi-
tionally, CD34 belongs to KRAS.AMP.LUNG_UP.V1_DN 
[120], a gene set based on the comparison between the hy-
per-expression of KRAS (a proto-oncogene; OMIM ID: 
190070) that carries the G13V activating mutation and cells 
without this construct, i.e., in favorable conditions for cell 
proliferation. Since in the BC patient in which this alteration 
was found there was, as explained above, a protein up-
regulation (Table 2), this might be a case where two different 
mechanisms are involved in BNPTP and in other model sys-
tems; alternatively, this information could be relevant for 
defining how the levels of the CD34 protein are finely tuned, 
once defined the status of KRAS. 
3.2.4. CDKN2A 
 Cyclin-dependent kinase inhibitor 2A (CDKN2A) is an 
oncosuppressor having at least three isoforms [121]. It is an 
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inhibitor of cell cycle progression and acts at the G1/S transi-
tion by suppressing the action of crucial cyclin-dependent 
kinases, such as CDK4 and CDK6 [122]. This gene also con-
tains another open reading frame coding for the ARF protein, 
which acts as an oncosuppressor as well [123]. The deletion 
or mutation of CDKN2A is frequently associated with neo-
plastic transformation in several tissues and organs, includ-
ing the bladder [124], while it has been shown that ARF deg-
radation is inhibited in cancer cells [125], suggesting that 
p16 and p19/ARF may act in complementary, inversely re-
lated cell cycle control pathways. 
 Since oncogenic KRAS-driven cancers require TBK1, 
and TBK1 silencing induces KRAS-dependent apoptosis 
(OMIM ID: 604834) the hit of CDKN2A in the gene set 
TBK1.DN.48HRS_UP [120] suggests that the negative inter-
ference with this oncogenic pathway might positively induce 
CDKN2A, while the tumor promoting conditions found in 
BNPTP are able to down-regulate it. Therefore, CDKN2A 
shows potential to be a gene that switches its levels (UP or 
DOWN) in response to specific anti- or pro- tumor stimuli, 
respectively. CDKN2A is also found in the gene set 
SNF5_DN.V1_DN [126], since the knockout of the tumor 
suppressor SNF5 (OMIM ID: 601607) lowers its mRNA 
levels, in pro-proliferative conditions. Therefore, the dys-
regulation of SNF5 might be a worsening factor for the 
down-regulation of this protein in BNPTP (instead, we rule 
out the case that there is any causal relationship since the 
downregulation of CDKN2A is at the level of gene deletion 
(confirmed in 4 patients) and not of mRNA or protein). Con-
sidering that SNF5 and SMARCB1 are synonymous, this 
analysis can be combined with that of SMARCB1 (see be-
low). Additionally, also CYCLIN_D1_KE_.V1_UP hits this 
gene [116]; this gene set is based on the overexpression of 
the putative oncogene CCND1 and therefore there is biologi-
cal compatibility between what observed for the gene set at 
the mRNA level and these four patients at the protein level. 
This could be invoked as a control mechanism for the down-
regulation of CDKN2A, but the fact that using this target 
gene (i.e., CCND1) would require inducing a cyclin makes 
this information hardly applicable, in our opinion. Finally, 
this gene belongs to P53_DN.V1_UP [21]; this means that, 
in the pro-proliferative conditions that characterize this gene 
set, the CDKN2A mRNA is upregulated, while the 
CDKN2A gene is DOWN (being deleted) in BNPTP. These 
two events are clearly not correlated and do not need to be 
commented further. 
3.2.5. Gli1 and Gli3 
 The GLI (glyoma associated oncogene) proteins are tran-
scription factors. They are effectors of the Hedgehog (Hh) 
signaling pathway and have a role in cell fate determination, 
proliferation and patterning in many cell types and most or-
gans during embryo development [127]. Their amplification 
causes neoplastic transformation in the central nervous sys-
tem, and Northern blot analysis showed that GLI mRNAs are 
expressed in embryonal carcinoma cells but not in most adult 
tissues [128]. Gli1 is a recognized oncogene [129] and its 
over-expression in mice causes the formation of basal cell 
carcinoma (BCC) [130]. Instead, Gli3 is not related to 
glyoma, BCC or other forms of neoplasia, but is essential for 
Gli1 expression in the somites during the muscle formation 
[131]. Its mutations are associated with several other dis-
eases, such as Greig cephalopolysyndactyly syndrome, Pal-
lister-Hall syndrome, preaxial polydactyly type IV, and 
postaxial polydactyly types A1 and B [132]. Gli3 may both 
act as an activator or repressor of transcription [133]. 
 GLI1 is one of the genes of the gene set WNT_ 
UP.V1_UP [134]: this is a typical case of a hyper-expressed 
oncogene (WNT1 (a.k.a. Wnt-1) (OMIM ID: 164820)) that 
induces the expression of a set of genes. Since in this gene 
set there are only genes up-regulated and GLI1 is up-
regulated too in BNPTP, it is possible or that WNT1 is di-
rectly upstream of GLI1 or that its activation is capable to 
worsen the phenotype observed in the presence of elevated 
levels of GLI1. Another interesting case is present for the 
second hit of GLI1: the gene set CYCLIN_D1_KE_.V1_UP 
[116] is based on the overexpression of CCND1 and there is 
compatibility both at the level of biological context (pro-
proliferative) and type of change (upregulation) between this 
gene set and this gene; additionally, the molecule involved 
(i.e., mRNA) is the same. This makes a relatively strong case 
for CCND1 being upstream and directly inducing the levels 
of GLI1 found in BNPTP, or, alternatively, this perturbation 
of cyclin D1 might worsen the phenotype of these patients. 
Finally, considering that the upregulation of WNT1 upregu-
lates CCND1 (this has been described as an early biological 
event) [135], it is possible to hypothesize that the pathway 
WNT1  CCND1  GLI1  is involved in BNPTP. Instead, 
only one gene set (CSR_LATE_UP.V1_DN) hits GLI3, but 
it is one of the 24 gene sets that we consider less usable for 
making this type of inferences. So, we cannot conclude any-
thing relevant about possible upstream events for GLI3, 
based on the available oncological signatures. 
3.2.6. HRAS, NRAS and KRAS 
 The small GTPase class of proteins called RAS (from the 
phrase “rat sarcoma”) includes three main members, i.e., 
HRAS, NRAS and KRAS. They are ubiquitously expressed 
in all human organs and their role is the intracellular signal 
transmission; they perform such a task by conformational 
changes induced by the hydrolysis of GTP into GDP. These 
changes are usually a response to an extracellular stimulus, 
passed through by specific receptors. RAS proteins transmit 
the signal by activating many biochemical cascades (such as 
Mitogen-activated protein kinases (MAPK)) and in this way 
control crucial cellular activities, such as cell proliferation, 
differentiation, and apoptosis [136, 137]. Mutations causing 
permanent activation of RAS polypeptides are oncogenic 
[138] and play a central role in bladder cancer formation 
[65]. Martinelli and collaborators showed that somatic mis-
sense mutations in RAS genes represent a recurrent event in 
pediatric/teenage embryonal RMS, accounting for approxi-
mately one fourth of the cases [40]. 
 HRAS is involved in a wide number of normal cellular 
processes, and its upregulation may be sometimes physio-
logical, as during rat liver regeneration [139]. Mutations in 
HRAS are also responsible of Costello syndrome, a multiple 
congenital anomaly and mental retardation syndrome [140]. 
KRAS has two isoforms called KRASA and KRASB, de-
rived by an alternative splicing, differing in the C-terminal 
regions, which are important for post-translational modifica-
tions causing alternative trafficking pathways and protein 
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localization [141]. Also deregulated KRAS is frequently 
involved in neoplastic transformation; in fact, 17 to 25% of 
all human tumors harbor an activating KRAS mutation 
[142]. Finally, also NRAS plays a central role in cell prolif-
eration and its uncontrolled activation may lead to neoplastic 
transformation. Mutations in position 17 (in all RAS mem-
bers) produce dominant-inhibitory proteins with higher af-
finities for exchange factors than normal RAS, impairing 
their functions [143]. NRAS mutations were identified in 
Noonan syndrome-6 [144] and in patients with congenital 
melanocytic nevus syndrome [145]. 
 HRAS is hit by LTE2_UP.V1_UP [146], but this gene set 
has been discarded based on pre-defined algorithm steps that 
we used for gene set selection (see Materials and Methods); 
for this reason, this analysis is unable to provide more bio-
logical insight and the main information available is that this 
gene was found mutated in two BNPTP (Table 2). NRAS 
belongs to the STK33_NOMO_UP gene set [106]; as men-
tioned in the ACTA2 paragraph, while the precise role of 
STK33 downstream of mutant KRAS is not fully clear [107-
109], and while some caution should be used in making in-
ferences based on AML cell lines, we consider reliable the 
information of Scholl et al. [106] about the fact that silenc-
ing STK33 has a strong anti-proliferative effect. This creates 
a biological conflict, since the UP/UP status for this gene set 
and NRAS (protein activity) is associated with anti- and pro- 
proliferative conditions in these two cellular environments, 
respectively; ultimately, also considering that the upregula-
tion of the NRAS mRNA is dependent on two events (muta-
tion of KRAS and STK33 knocked down) we consider this 
outcome inconclusive for NRAS. Instead, the situation of 
match between NRAS and the gene set YAP1_UP [147] is 
quite interesting: the over-expression of the YAP1 (OMIM 
ID: 606608) oncogene [148] induces NRAS, and this makes 
YAP1 a protein potentially capable to amplify NRAS mRNA 
levels and worsen the phenotype of these patients. Finally, 
no gene set hits KRAS, while it is upregulated in BNPTP. 
This outcome raises the odds that the mutation of this proto-
oncogene is an early event of this cancer’s onset; therefore, 
the most important biochemical events concerning this gene 
are rather found downstream. 
3.2.7. KRT20 
 Cytokeratin 20 is a type I cytokeratin encoded by the 
KRT20 gene. It is an integral intermediate filament compo-
nent and a major cytoskeletal keratin of the intestinal epithe-
lium. Its principal localization is in the intestinal and gastric 
mucosa, and in several other epithelia; indeed, it is also pre-
sent in superficial (and, occasionally, intermediate) cells of 
the bladder urothelium (urothelial umbrella cells). As such, it 
can be used to identify a range of adenocarcinomas arising 
from epithelia, and by immunohistochemistry it is frequently 
found in colorectal cancer, transitional cell carcinomas and 
Merkel cell carcinoma [149]. In combination with CK7, it is 
a useful marker of bladder cancer [150]. 
 We found a hit for this gene: in fact, a KRAS mutation 
downregulates KRT20 (gene set KRAS.600.LUNG. 
BREAST_UP.V1_DN [151]), whose activity is UP in our 
collection of clinical reports. The examined KRAS mutation 
is found in breast and lung malignancies, and, overall, these 
data point towards a tissue-specific KRT20 status. 
3.2.8. MUC1 
 Mucin 1, cell surface associated (MUC1) is a transmem-
brane mucin (high molecular weight, heavily glycosylated 
protein) with the function of tissue protection from patho-
gen-mediated infections, but is also involved in signal trans-
duction [152]; it is an oncoprotein. Being an epithelial pro-
tein, its expression is usually associated with carcinomas (of 
colon, breast, ovary, lung and pancreas), but it has also been 
found in mesenchymal tumors (such as synovial sarcoma and 
ovarian granulosa cell tumors) [153]. Some Authors hy-
pothesize that its upregulation gives an advantage to cancer 
cells against the anti-tumor immune response [154]. Moreo-
ver, it has also been shown that the cytoplasmic portion of 
MUC1 may interact with p53, promoting the anti-apoptotic 
properties of the latter [155]. Apoptosis may also be im-
paired by the MUC1-mediated phosphorilation of Akt, caus-
ing the up-regulation of Bcl-2 and Bcl-xl that in turn prevent 
the release of the cytochrome c from the mitochondria [156]. 
Finally, the over-expression of MUC1 promotes the stabili-
zation of beta-catenin, resulting in the initiation of EMT, 
which promotes invasiveness [157]. 
 This gene belongs to a very interesting gene set, 
ERB2_UP.V1_UP [158], produced by collecting the genes 
that become upregulated after inducing the oncogene 
ERBB2 (OMIM ID: 164870); since the protein MUC1 is 
upregulated too, ERBB2 should be considered or as a possi-
ble upstream gene for MUC1 or potentially involved in a 
pathway that impacts the same gene in pro-proliferative con-
ditions. 
3.2.9. MYF5 and MyoD1 
 Myogenic factor 5 (MYF5) is a key protein in the regula-
tion of muscle differentiation; MYF5 and MyoD1 (myogenic 
differentiation 1) are transcription factors belonging to the 
family of proteins known as myogenic regulatory factors 
(MRFs). Without the contemporary presence of Myf5 and 
MyoD, myogenic cells fail to progress normally during the 
determination stage of myogenesis [159]. MYF5 and 
MyoD1, and particularly the latter, are able to bind hundreds 
of muscular gene promoters and drive the myoblast prolif-
eration; MyoD1 cooperates with the Retinoblastoma protein 
(Rb) to transcribe later markers of differentiation [160] and 
in inducing cell cycle arrest in terminally differentiated 
myoblasts, through the regulation of Cyclin D1 [161]. 
 NOTCH_DN.V1_UP is a gene set created investigating 
the cell cycle deregulation induced by NOTCH [162], a gene 
having a rather elusive nature, which is context-dependent 
[163] and MYF5 belongs to it. Since it has been described 
that in BC NOTCH acts as a tumor suppressor [164] and our 
evaluations are referred, as much as possible, to the biologi-
cal background of BNPTP, the following analysis is based 
on NOTCH intended as oncosuppressor. MYF5 is up-
regulated both in the conditions tested for the definition of 
this gene set and in BNPTP, in the presence of what we as-
sume would be a pro-growth stimulus on the side of the gene 
set and of a tumor background in BNPTP. Technically 
speaking, this might be a case where NOTCH signals up-
stream of MYF5, directly or indirectly. However, the con-
siderable difference among these two biological models (in-
deed, this gene set was defined in T-cell acute lymphoblastic 
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leukemia cell lines) and the contradictory nature of NOTCH 
highlighted above suggest caution about establishing this 
biochemical link. Instead, no inducer gene or mechanism can 
be hypothesized for explaining the downregulation of 
MyoD1, since no hit was found for it, which brings up the 
hypothesis that MyoD1 acts as a specific biomarker of pedi-
atric/teen BC. 
3.2.10. NCAM1 
 Neural cell adhesion molecule 1 (NCAM1) is a glycopro-
tein expressed on the surface of neurons, glia, skeletal mus-
cle and natural killer cells. It has a role in cell-cell and cell-
matrix adhesion [165], neurite outgrowth, synaptic plasticity, 
learning and memory [166]. NCAM shares many features 
with immunoglobulins and indeed is considered a member of 
the immunoglobulin superfamily [167]. Some reports link its 
expression to cancer, especially to neuroblastoma, malignant 
lymphomas of T-NK cell origin, multiple myeloma, mela-
noma, some cancers of epithelial origin [168], small cell 
lung cancer, neuroblastoma, rhabdomyosarcoma, brain tu-
mors, acute myeloid leukemia [169] and, occasionally, large 
B-cell lymphoma [170, 171]. 
 The NCAM1 protein is found up-regulated in one patient, 
but is downregulated in AKT_UP.V1_DN [172]. Since this 
gene set derives from the hyper-expression of Akt1, an on-
cogene (OMIM ID: 164730), we are in the presence of an 
antagonistic way to be upstream of NCAM1, a fairly good 
example of a gene which may play different roles in different 
tissues or contexts [173]. Additionally, the gene set 
KRAS.600.LUNG.BREAST_UP.V1_UP [151] is also hit by 
this gene; this suggests that oncogenic KRAS might be sig-
naling towards NCAM1 or that it has the potential to worsen 
the observed phenotype. This result, while important, does 
not add new key genes to the BNPTP gene list, since KRAS 
is already among those of primary relevance for these pa-
tients. This gene also belongs to MTOR_UP.V1_DN [172], 
which means that with a pro-proliferative cell background 
(upregulation of MTOR; OMIM ID: 601231) NCAM1 is 
downregulated, while, in the pro-growth conditions of 
BNPTP, the same gene is upregulated. This outcome sug-
gests, among other possibilities, that pediatric/teen BC pos-
sibly is an MTOR-independent tumor [174]. 
3.2.11. NF1 
 Neurofibromin 1 (NF1) is the gene responsible for neu-
rofibromatosis type I (named NF1 as well), a tumor disorder 
affecting the nervous system. NF1 is a cytoplasmic protein 
predominantly expressed in neurons, Schwann cells, oli-
godendrocytes, and leukocytes. It plays an important role in 
cell proliferation pathways, such as the RAS-cyclic AMP 
pathway and the ERK/MAP kinase cascade, in adenylyl cy-
clase activation, and in cytoskeletal assembly; mutations are 
usually discovered in the heterozygous state [175]. In par-
ticular, its action on HRAS is inducing hydrolyzation of 
GTP, thus inactivating it; consequently, NF1 acts as a tumor 
suppressor [176]. Moreover, mutations in this gene have 
been identified in other clinical conditions, such as juvenile 
myelomonocytic leukemia [176], Watson syndrome [177], 
desmoplastic neurotropic melanoma (DNM) [178], glioblas-
toma [179], and breast cancer [180]. 
 Notably, while the nature of NF1 can be hardly defined 
looking at the literature about BNPTP (Table 2), the hit ma-
trix based on OSMSD points in the direction of an upregula-
tion: we suggest to investigate this topic further. Indeed, we 
found that: i) it belongs to P53_DN.V2_UP [181], which is a 
gene set where the tumor suppressor TP53 is silenced, thus 
bringing to the upregulation of a number of genes, among 
which there is NF1. For consistency with this result, the odds 
that the NF1 mRNA is upregulated are higher than for the 
opposite hypothesis; ii) TBK1.DF_DN [120] is also hit by 
NF1; for this gene set, the gene TBK1, upon which the 
proto-oncogene KRAS relies for cancer induction, is si-
lenced, thus making the cell condition less favorable for 
growth. This would better match the case that NF1 is 
upregulated, which, in turn, would raise its chances to be a 
very sensitive gene, which reacts to pro- or anti- growth 
stimuli moving its levels in opposite directions. Instead, if 
this conflict was resolved assuming that NF1 is downregu-
lated in BNPTP, this would be the case of a gene that is 
DOWN independently of the growth condition, and rather 
depending on the biological context; iii) NF1 belongs to 
WNT_UP.V1_UP [134]: therefore, a pro-proliferative ex-
perimental stimulus (due to the upregulation of WNT1) in-
duces NF1 mRNA. If NF1 is actually upregulated, this 
means that WNT1 might be an upstream inducer or, at least, 
a worsening factor for BNPTP. 
3.2.12. PTCH1 
 Patched 1 is a tumor suppressor, transmembrane protein 
and a receptor for the secreted molecule ‘sonic hedgehog’ 
that plays a role in the formation of embryonic structures and 
in tumorigenesis. PTCH1 acts as an inhibitor of the ‘smooth-
ened’ protein, a G protein-coupled receptor [182]; when 
‘sonic hedgehog’ binds PTCH1, smoothened is released and 
signals cell proliferation [183]. Interestingly, Gli1 regulates 
PTCH expression in a cell type-specific manner [184]. Muta-
tions in PTCH1 cause Gorlin syndrome, basal cell carcino-
mas (BCC), nevoid basal cell carcinoma syndrome 
(NBCCS), medulloblastoma and rhabdomyosarcoma [185]. 
 E2F3_UP.V1_UP [186] is a gene set containing genes 
up-regulated upon over-expression of E2F3 (OMIM ID: 
600427) [187]; since in both cases (BNPTP and the experi-
mental conditions tested for defining this gene set) we are in 
pro-cell growth conditions, we deem or that E2F3 is up-
stream of PTCH1, since its mRNA is also upregulated in 
BNPTP, or that E2F3 has the potential to worsen the pheno-
type of these patients. 
3.2.13. PTPN11 
 Tyrosine-protein phosphatase non-receptor type 11 is an 
intracellular enzyme that is widely expressed in human tis-
sues and is particularly abundant in heart, brain, and skeletal 
muscle. It is involved in mitogenic activation, metabolic con-
trol, transcription regulation, and cell migration. Dominant 
mutations of this gene can cause Noonan syndrome [188], 
LEOPARD syndrome [189], juvenile myelomonocytic leu-
kemia [190], and metachondromatosis [191]. PTPN11 muta-
tions, although at low frequency, are also found in several 
other human cancers [192]. These data suggest that PTPN11 
is a proto-oncogene; however, a recent report shows that it 
may also act as a tumor suppressor, at least in hepatocellular 
carcinoma [193]. 
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 We found a match between a gene set, ATM_ 
DN.V1_DN [181], generated in pro-growth conditions 
(silencing of the tumor suppressor ATM (OMIM ID: 
607585)), and PTPN1, which is included in the list because 
of an activating mutation, with a conflict DOWN/UP 
between gene set and gene. An analogous situation happens 
for the gene set P53_DN.V2_DN [181], where the silencing 
of TP53 down-regulates a number of genes, and among them 
PTPN11. Considering that ATM phosphorylates and acti-
vates TP53 [194], a general pathway based on these genes is 
the following: ATM  TP53  PTPN11 . If the pediat-
ric/teen BC data (PTPN1 UP) were confirmed, this might 
suggest that PTPN11 activation in BNPTP is independent of 
this tumor suppressor signaling pathway. The possibility to 
regulate the upstream levels of either or both these tumor 
suppressors for counteracting the activation of PTPN11 
looks hardly applicable in medicine, since it would involve 
“tampering” with tumor suppressors. 
3.2.14. SMARCB1 
 SWI/SNF-related matrix-associated actin-dependent 
regulator of chromatin subfamily B member 1 (SMARCB1) 
is a chromatin remodeling factor. It is a subunit of the 
SWI/SNF ATP-dependent chromatin-remodeling complex 
whose function is relieving repressed chromatin state and 
promote gene expression. It is a tumor suppressor that is 
frequently deleted in pediatric/teen malignant rhabdoid tu-
mors (MRT) [195]. Mutations in this gene were also identi-
fied in i) choroid plexus carcinomas, ii) a subset of central 
primitive neuroectodermal tumors and medulloblastomas 
[196], iii) schwannomatosis 1 and iv) meningiomas [197]. Its 
loss of function in MRT-derived cells causes polyploidy and 
chromosomal instability, a condition that can be reverted 
upon its re-expression [198]. Interestingly, it has been also 
demonstrated that SMARCB1 is able to drive the expression 
of Gli proteins, by acting as a negative regulator; thus, it 
influences the Gli-Hh signaling pathway (see above) [199]. 
 In the presence of inactivation of the Snf5 tumor suppres-
sor (OMIM ID: 601607), i.e., of the experimental conditions 
that allowed defining the gene set SNF5_DN.V1_DN [126], 
SMARCB1 is down-regulated; however, since SMARCB1 
and Snf5 are just synonymous, it is expected that the mRNA 
levels of a knocked out gene drop. On the side of BNPTP, 
SMARCB1 is DOWN, at the level of gene deletions, and this 
gene alteration is quite important (5 cases are reported in 
Table 2). Notably, out of 189 gene sets tested, only one, 
which is defined by experimentally targeting this gene, is 
able to lower the expression of SMARCB1 mRNA; this sug-
gests that the oncogenicity of SMARCB1 does not depend 
on nor is modulated from cancer-related upstream events that 
are collected in the OSMSD. 
3.2.15. TP53 
 Tumor protein p53 (TP53) is a tumor suppressor gene 
and the most frequently mutated gene (up to 50%) in human 
cancer [200]. Despite its name, derived by its molecular 
weight, it is now known that the TP53 gene may encode at 
least 12 different protein isoforms, ranging from 28 to 53 
kDa [201]. TP53 encodes proteins that bind to DNA and 
regulate gene expression to prevent mutations of the genome 
[202]. It has been defined “guardian of the genome”, as it 
plays important roles in apoptosis, angiogenesis, genomic 
stability, miRNA processing, cell cycle control, aging, in-
duced pluripotent stem cell generation; its protein isoforms 
are regulated by phosphorylation, ubiquitination, acetylation, 
methylation, through the miRNA targeting of its transcripts, 
and by the interaction with other proteins. 
 This gene is only hit by the gene set P53_DN.V2_UP 
[181], where the silencing of TP53 induces the upregulation 
of the TP53 mRNA, possibly because the cells used try to 
compensate for this knockdown. However, the not fully un-
derstood reason for this gene set outcome, the fact that it is 
hard to make this type of “circular” inferences (the targeted 
gene in the gene set is also one of the differentially ex-
pressed genes), and the observation that the behavior of 
TP53 in BNPTP is somehow ambiguous (Table 4), make this 
case, in our opinion, completely undefined. 
3.2.16. VIM 
 Vimentin (VIM) is a type III intermediate filament whose 
main function is the localization and anchoring of the organ-
elles in fixed positions inside the cytosol [203]; in the form 
of a secreted phosphorilated homodimer, it plays a role also 
in the immune response [204]. Typically, VIM is expressed 
in mesenchimal tissues, and for this reason it is frequently 
used as a specific marker for mesenchimally-derived tissues 
and for their transformed counterparts, i.e., sarcomas. 
 VIM belongs to PTEN_DN.V1_DN [205], which means 
that when the tumor suppressor PTEN (OMIM ID: 601728) 
is silenced (pro-growth condition) VIM is downregulated. 
However, the VIM protein is actually upregulated in 
BNPTP, thus providing evidence for an upstream event that 
might reduce its level of activation, but in pro-growth condi-
tions. Such data allow making several hypotheses: i) this 
upregulation might not be a key event in pediatric/teen BC, 
ii) there is a specificity in BNPTP with respect to this gene, 
iii) the upstream event (silencing of PTEN) is a possible con-
trol mechanism for the upregulation of VIM, but would re-
quire to be very finely tuned. Also WNT_UP.V1_DN [134], 
generated in pro-growth conditions (upregulation of WNT1) 
is hit by VIM. The discrepancy between the gene set 
(DOWN) and gene (UP) polarity allows making some hy-
potheses, ranging from the possibility to evaluate the use of 
this event as an upstream regulator of VIM, which is made 
complicated by the nature of the possible action (upregula-
tion of an oncogene) to simply assuming that VIM has an 
independent behavior with respect to this tumor progression 
pathway. Finally, VIM hits P53_DN.V1_DN (a gene set 
based on mutant p53 and, as such, identified in samples that 
are in pro-proliferative conditions) [21]. However, in this 
gene set VIM is DOWN at the mRNA level, so we have an-
other case of DOWN/UP conflict between gene set and gene; 
this outcome suggests that in pediatric/teen bladder cancers 
VIM is regulated in a p53-independent way. 
3.2.17. WT1 
 Wilms tumor protein 1 (WT1) is a transcription factor 
and plays a central role in the normal development of the 
urogenital system. WT1 acts both as a tumor suppressor and 
an oncogene, according to the splice form involved. It causes 
an embryonic kidney malignancy, namely the Wilms’ tumor; 
some Authors proposed that this neoplastic transformation is 
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mediated by abnormally persistent renal stem cells (nephro-
genic rests), which retain embryonic differentiation potential 
[206]. 
 This gene is only hit by gene sets (namely, ATF2_ 
S_UP.V1_DN, ESC_V6.5_UP_EARLY.V1_UP and LEF1_ 
UP.V1_UP) that we have decided not to include in this 
analysis, since they do not meet the quality standards defined 
for the gene set selection. Readers interested in learning 
more about possible upstream events for this gene, whose 
protein is upregulated in BNPTP, can especially refer to the 
last two, since they share the same polarity (i.e., UP) of WT1 
in BNPTP. 
4. DISCUSSION 
 There is no particular reason to hypothesize that rare dis-
eases in general and, more specifically, rare types or sub-
types of cancer, have a different level of complexity when 
compared with more common diseases [207, 208]. Intrigu-
ingly, personalized medicine is rather showing that even 
common pathologies (e.g. cancers with the highest morbid-
ity) are a collection of rare genomic diseases [209]. How-
ever, there is a clear and remarkable difference between 
common and rare diseases: the former are usually the sub-
jects of strong research efforts, which generate abundant data 
and useful knowledge, while investigations performed and 
financial resources invested for the latter are much less, 
sometimes negligible. Data available for infrequent patholo-
gies are sparse and often based on single cases, which are 
treated by physicians living in different countries and, as 
such, are hardly seen as a whole [210, 211]. Additionally, the 
level of knowledge transmission is generally insufficient 
[212] and many physicians and researchers that directly treat 
or investigate these cases lack the training for properly per-
forming multi-step data analyses similar to those presented 
in this paper or deal with “knowledge barriers”, which may 
have many causes [213]. These facts make much more chal-
lenging to find effective strategies for fighting rare diseases, 
in particular when it comes to the contextualization (i.e., the 
enhancement of our understanding of a biological object X, 
taking into consideration known biological factors, condi-
tions, and mechanisms that are in some relationship with X) 
of the gene alterations found in individual patients. There-
fore, every computational or methodological approach that 
rigorously connects and leverages on the existing informa-
tion is a welcome addition to the literature. 
 The goal of this paper is dual: on the one side to under-
stand the aggregate properties of genes that have been de-
scribed as altered in BNPTP, using GO-based methods, and 
on the other side i) to suggest a possible etiology for the gene 
alterations found or ii) to determine oncological mechanisms 
that regulate/deregulate/act upstream of the same genes. The 
shortage of data available made this goal hard to achieve for 
several reasons. First of all, in most cases only one patient is 
linked to a specific gene deregulation, thus the data collected 
so far would greatly benefit of additional reports, possibly 
obtained using similar methods, in order to confirm these 
gene roles. Moreover, the classification of these tumor sam-
ples is not always straightforward; for example, the gene 
SMARCB1 was described both in pure and malignant rhab-
doid tumors, but the Authors of these papers (see Table 2) do 
not specify if these two tumors should be regarded as two 
different subtypes or not. In general, classification issues 
may help to explain why i) the same tumor is or is not posi-
tive for the same gene, and ii) different research groups char-
acterized the same tumor based on different markers (see, for 
example, [15] and [45]). The identified genes are heteroge-
neous not only because there are biological differences 
among distinct tumor types/subtypes, but also because the 
techniques used by different research groups are different 
and methods have been dramatically improving (for exam-
ple, the research of Stratton et al. [38] was published when 
DNA microarrays did not exist). 
 We decided to pursue a GO approach for the following 
reasons: 1) GO-based methods rely on categorical data 
analysis and this allows statistically assessing which biologi-
cal themes are relevant despite the level of gene heterogene-
ity; 2) we were looking for biological processes that could be 
identified without any bias due to the analyst’s knowledge 
about this subject; 3) the article published by Hoadley et al.
about the Pan-Cancer-12 collection [214] shows that the or-
gan involved in a malignancy often determines a distinct 
genomics signature, and we were interested in understanding 
which biological factors join the tumors listed in Table 1.
Notably, looking at the 21 genes of BNPTP independently 
shows a strong predominance of proliferative genes; how-
ever, this approach fails to detect a number of biological 
processes, which are associated with statistically significant 
GO-BP p-values and may be involved as well in this cancer 
onset. Since we are aware that some of these p-values are 
overly optimistic and may be driven by the limited number 
(i.e., 21) of genes available, we used a semantic selection 
process, which reduced the most important GO-BPs to 26. 
Looking at the semantic network of these 26 GO categories, 
we found that the interplay between genes involved in dif-
ferentiation/development and regulatory pathways may be 
crucial: in particular, the role of Rac signal transduction, of 
the cytoskeleton and of response mechanisms to abiotic 
stimuli deserve to be investigated further. The fact that the 
analyzed genes are ontologically grouped into two relatively 
coherent subgraphs suggests that each of them may represent 
a main route of cancer development in these young patients. 
Focusing on the left subgraph of Fig. 1, there are no clear 
clues about why most of its GO terms showed up. However, 
the specific nature and behavior of pediatric/teen BC [2] 
might partially explain this outcome. In particular, it is 
tempting to envisage that alterations during the urogenital 
development may influence the normal homeostasis of blad-
der cells in young patients, ultimately leading to the neoplas-
tic transformation. Indeed, there seems to be a specific age 
threshold dividing pediatric/teenage and adult bladder pa-
tients, set at around 19 years of age [2, 17]. Therefore, a rea-
sonable hypothesis is that the transformation relies on the 
left subgraph of GO-BP terms, while the GO categories of 
the right subgraph are more related to abnormal cell growth 
and cancer development. As in every similar analysis, the 
GO categories found in this network can be better under-
stood looking at the biological features of the genes that be-
long to each GO term (see Tables 3 and S1). Indeed, in an 
extremely simplified way, the 21 genes found in BNPTP can 
be grouped into four classes, based on their potential activ-
ity: i) CD34, WT1, ACTA2, and VIM may play heterogene-
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ous roles with respect to cellular differentiation; ii) Gli1, 
Gli3, PTCH1, SMARCB1, MYF5, and MyoD1 may specifi-
cally affect muscle (one of the two main tissues of the blad-
der) cell differentiation; iii) KRT20, Muc1, and NCAM1 
may specifically affect the epithelial (the other main tissue of 
this organ) differentiation; iv) ALK, CDKN2A, RAS pro-
teins, NF1, PTPN11, and TP53 may drive and/or contribute 
to this carcinogenesis with complex and multifaceted mo-
dalities. To better understand the divide between pre-adults 
and adults, genes involved in adult bladder cancer should be 
analyzed with GO algorithms identical or equivalent to those 
used in this paper, looking for differences and similarities in 
the GO terms retrieved. 
 As for the gene set analysis, we have been exploiting the 
knowledge produced by GSEA and related methods and the 
information stored in the Molecular Signatures Database 
because: a) GSEA, PAGE, GLAPA, ASSESS and similar 
methods show that it is statistically beneficial aggregating 
tens or hundreds of genes and analyzing them as a whole, for 
robustness [21-24]; b) results previously obtained applying 
gene set-based methods prove that it is effective and useful 
making inferences on biomedical samples through statistical 
tests where the hypotheses that sets of genes act as biological 
“cliques” are based on experiments performed on heteroge-
neous biological models, both in vitro and in vivo; c) gene 
set information has a precise directionality and polarity (an 
experimental stimulus induces a set of genes and represses 
another set of genes) and all the genes belonging to a gene 
set are “weighted” in the same way; d) the presence of a 
gene in a gene set is associated with a probability (calculated 
as (# genes in the gene set) / (# genes in the genome)) that, 
even in the most unfavorable case (for NFE2L2.V2, which is 
the largest gene set of OSMSD), is well below 5% (i.e., p-
value < 0.05) and usually is (much) lower; e) the Molecular 
Signatures Database collects and annotates gene sets of on-
cological relevance and makes these data publicly available 
for analyses and meta-analyses [21]. The hit matrix of 
BNPTP has many types of information, some of good and 
some of insufficient biological quality (evaluated in terms of 
compatibility between type of gene set experiment and bio-
logical status of these patients), as it is expected by a broad-
spectrum analysis like this. However, the well-defined 34 
cases that we comment in this paper as hits supported by 
some type of biological evidence (either concordant or dis-
cordant, in terms of compatibility between pro- and anti- 
growth background, with what found in altered genes of 
BNPTP), allowed us to formulate novel hypotheses about the 
involvement of some (proto)oncogenes and (putative) tumor 
suppressors; hopefully, this list of candidate genes will 
stimulate more biological and clinical research on bladder 
cancer in pre-adult patients. The case of ACTA2 is quite 
compelling, since its status in BNPTP is in disagreement 
with all the indications provided by our gene set analysis; 
therefore, this is the case of a meta-analysis that hypothe-
sizes the redefinition of a gene role. Redefinitions and reas-
sessments are not uncommon outcomes of meta-analyses; for 
instance, the aforementioned paper by Hoadley et al. allowed 
reevaluating the subtype definition of breast cancer samples, 
showing that luminal and HER2 (i.e., ERBB2/HER2) sub-
types can effectively be joined into a unique group, from a 
genomics standpoint [214]. 
CONCLUSION 
 In adults, more than 50% of muscle invasive BC (MIBC) 
samples harbor mutations in the gene TP53, which is the 
major gene player of BC [28]. Instead, our PubMed searches 
found only one patient out of 25 examined (i.e., 4%) with an 
involvement of TP53 (Table 2) and the results concerning 
this gene obtained through our computational analyses are 
inconclusive/undefined. The case of this 18 year old male is 
also quite ambiguous, since he had two alterations with ap-
parently opposite effects (namely, an early stop codon with, 
likely, a loss of function, and an overexpression, probably 
dependent on the other allele (see the Results section)). Re-
markably, TP53 may be either inactivated or upregulated in 
adult BC samples [28], yet this usually does not happen in 
the same patient [28]. Additionally, the oncogene FGFR3 
(OMIM ID: 134934), which is the second most mutated gene 
in adult BC (found upregulated in up to 80% of non-MIBC 
and 40% of MIBC [28]) to the best of our knowledge has 
never been found mutated in BNPTP, even when mutations 
of this gene were specifically looked for [17]. Consequently, 
the two main genes involved in BC formation in adults seem 
to be less important in BNPTP. Notably, our results allowed 
identifying two genes potentially involved in BC of pediatric 
and teen patients, namely CTIP and WNT1, which are not 
established BC markers in adults. More specifically, a Pub-
Med search using “CTIP bladder” does not find any relevant 
paper (as to mid-June, 2015), while a search based on the 
same phrase with common web search engines allows re-
trieving only three articles: i) one analyzing CTIP variants in 
MIBC, mostly in the framework of DNA damage signaling 
and repair, which did not find any significant association 
between carriage of the called variants and overall survival 
[215], ii) one showing the cell cycle-specific expression of 
CTIP and its interaction with BRCA1 in a BC cell line [216], 
which is consistent with our analyses about CD34 (see the 
paragraph about this gene in the Results), and iii) one false-
positive result due to the fact that the Authors (working on 
NIH 3T3 cells) were using as a reference the previous paper 
[217]. A similar PubMed search was performed for WNT1. 
In this second case we were able to retrieve two papers: a) 
one investigating the relationship between WNT1 and BC, 
but in an indirect and purely associative way (involving the 
gene TERE1, whose locus is indeed related to BC) [218], 
and b) one even more indirect discussing Wnt and Fgf genes 
and reporting the association between a cluster of Fgf genes 
and BC [219]. Based on these query outcomes, the involve-
ment of CTIP and WNT1 in the signaling pathways of 
BNPTP, if confirmed experimentally, would be a novelty in 
the genetic landscape of urothelium transformation. 
 Our analyses allowed identifying seven other genes po-
tentially involved in BNPTP and whose presence was some-
how more expected, since their role in adult BC is supported 
by the literature. These genes are: 1) ERBB2 [220, 221], 2) 
CCND1 [222], 3) YAP1 [223, 224], 4) BRCA1 [225, 226], 
5) RB1 [227, 228], 6) RBL2/p130 [229, 230], and 7) E2F3 
[231]. An analysis of the expression patterns and mecha-
nisms of these seven genes in adults compared (as much as 
possible) with BNPTP is omitted, because it is beyond the 
scope of this article. Altogether, our results and the literature 
suggest that some BC genes are likely active in an age-
dependent fashion while others are shared between pre-
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adults and adults; this would explain the observed differ-
ences in the formation, development and behavior of BC in 
these two broad age groups [2]. Some of our results may be 
especially divergent from the outcomes of adults also be-
cause children have BC types/subtypes that are extremely 
rare in adults (for example, RMS or rhabdoid tumors) [232]. 
 It is our belief that contextualization methods are among 
the most powerful tools for making gene therapy, personal-
ized medicine and advanced medical approaches [233-235] 
available also to BNPTP and, more in general, to patients 
with rare diseases. We anticipate that some hypotheses de-
scribed in this article may not be confirmed experimentally; 
however, several mechanisms and genes that are listed in the 
Results section are novel and warrant future research for 
precisely defining their role in BNPTP. Additionally, the set 
of supplementary data and the key steps for using them (see 
the Materials and Methods section) allow anyone who is 
interested in this subject to formulate more hypotheses, pos-
sibly expanding the grid of analyzed cases beyond what we 
have already done. In the light of the recent production of 
genomics data about BC in adults [236] and of the differen-
tial BC responsiveness to therapy based on genomics sub-
types [237], it would be very valuable to connect and com-
pare as much as possible pediatric/teen and adult cases ex-
tensively and at a molecular level. It is our intention to con-
tinue investigating these bladder malignancies using ad hoc 
computational methods, which aim to fill the gap of knowl-
edge between pre-adults and adults and to propose computa-
tionally-derived therapeutic strategies. 
LIST OF ABBREVIATIONS 
BC = Bladder cancer 
BNPTP = Bladder neoplasms in pediatric and teen 
patients 
GO = Gene ontology 
OMIM = Online mendelian inheritance in man 
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